Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Mundipharma's Mundesine approved in Japan

Becky Simon
April 3, 2017 9:29 PM UTC

Mundipharma International Ltd. (Cambridge, U.K.) said Japan's Ministry of Health, Labor and Welfare approved Mundesine forodesine (BCX-1777) to treat relapsed or refractory peripheral T cell lymphoma. The approval is the first in the world for the purine nucleoside phosphorylase (PNP) inhibitor, the company said.

Mundipharma did not respond to inquiries regarding Mundesine's launch or pricing. In a statement, the company said it is working to ensure access in Japan "as early as possible."...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Biocryst Pharmaceuticals Inc.

Mundipharma International Ltd.